Trial Profile

A randomised, placebo controlled phase 3 trial of Cannabidiol soft gel capsules in insomnia-related indications

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Mar 2025 According to an Avecho Biotechnology media release, the company announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG for the commercial rights to Avecho's Phase III cannabidiol capsule for insomnia in Australia. Sandoz has agreed to an upfront licensing fee of US$3M (approx. A$4.8M[1]) for the exclusive commercial rights to the CBD product for insomnia in Australia. company will continue to fund and oversee the ongoing Phase III trial.
22 Dec 2022 According to an Avecho Biotechnology media release, company has received ethics approval for this trial.
04 Aug 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com